Prolonged clinical benefit from the maintenance hormone therapy inpatients with metastatic breast cancer

Breast

Volumn 22, Issue 6, 2013, Pages 1205-1209

  Lim, Seungtaek ^a   Lee, Soohyeon ^a   Han, Jungwoo ^a   Park, Byeong Woo ^a   Kim, SeungIl ^a   Park, Seho ^a   Kim, Joo Hang ^a   Choi, Hye Jin ^a   Sohn, Joohyuk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; ER; Hormone therapy; Maintenance; MBC; MHT; MPA; OS; PFS; PR; RECIST

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; FULVESTRANT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRASTUZUMAB;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; INSOMNIA; LYMPH NODE METASTASIS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; VAGINA BLEEDING; VISCERAL METASTASIS; WEAKNESS;

BREAST CANCER; ER; ESTROGEN RECEPTOR; HORMONE THERAPY; MAINTENANCE; MAINTENANCE HORMONE THERAPY; MBC; MEDROXYPROGESTERON ACETATE; METASTATIC BREAST CANCER; MHT; MPA; OS; OVERALL SURVIVAL; PFS; PR; PROGESTERONE RECEPTOR; PROGRESSION FREE SURVIVAL; RECIST; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84887165390     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.08.013     Document Type: Article

References (16)

1. Stockler M., Wilcken N., Coates A. Chemotherapy for advanced breast cancer - how long should it continue?. Breast Cancer Res Treat 2003, 81:49-52.
2. Coates A., Gebski V., Bishop J.F., Jeal P.N., Woods R.L., Snyder R., et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. NEngl J Med 1987, 317:1490-1495.
3. Harris A.L., Cantwell B.M., Carmichael J., Wilson R., Farndon J., Dawes P., et al. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 1990, 335:186-190.
4. Muss H.B., Case L.D., Richards F., White D.R., Cooper M.R., Cruz J.M., et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. NEngl J Med 1991, 325:1342-1348.
5. Ejlertsen B., Pfeiffer P., Pedersen D., Mouridsen H.T., Rose C., Overgaard M., et al. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer 1993, 29A:527-531.
6. Falkson G., Gelman R.S., Pandya K.J., Osborne C.K., Tormey D., Cummings F.J., et al. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. JClin Oncol 1998, 16:1669-1676.
7. Yvelines F., Lorient Cedex F. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. JClin Oncol 2000, 18:3115-3124.
8. Gregory R.K., Powles T.J., Chang J.C., Ashley S. Arandomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast. Eur J Cancer 1997, 33:2194-2197.
9. Nooij M.A., de Haes J.C., Beex L.V., Wildiers J., Klijn J., Becquart D., et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clinical outcomes and oncologists' preferences. Eur J Cancer 2003, 39:614-621.
10. Gennari A., Amadori D., De Lena M., Nanni O., Bruzzi P., Lorusso V., et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. JClin Oncol 2006, 24:3912-3918.
11. Alba E., Martin M., Ramos M., Adrover E., Balil A., Jara C., et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. JClin Oncol 2004, 22:2587-2593.
12. Beslija S., Bonneterre J., Burstein H., Cocquyt V., Gnant M., Goodwin P., et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007, 18:215-225.
13. Bertelli G., Garrone O., Bertolotti L., Occelli M., Conforti S., Marzano N., et al. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 2005, 68:364-370.
14. Kloke O., Klaassen U., Oberhoff C., Hartwich G., Szanto J., Wolf E., et al. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Breast Cancer Res Treat 1999, 55:51-59.
15. Alba E., Ruiz-Borrego M., Margeli M., Rodriguez-Lescure A., Sanchez-Rovira P., Ruiz A., et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat 2010, 122:169-176.
16. Park Y.H., Jung K.H., Im S.A., Sohn J.H., Ro J., Ahn J.H., et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. JClin Oncol 2013.